Liver Health

Liver Health After Age 60

How the liver changes with age, what conditions become more common after 60, and the evidence-based steps that best protect liver function in later life.

The liver is often described as the body’s silent organ — it performs over 500 essential functions without any sensation of effort, and it does not typically signal distress until its capacity to compensate has been substantially exceeded. After age 60, this silence takes on additional significance. Age-related changes in liver structure and function are well documented, yet most adults have no idea their liver’s processing capacity has changed, or that the medications, supplements, and lifestyle habits that were fine at 45 may carry different implications at 65.

This article explains what actually changes in the liver with aging, which conditions are significantly more common in adults over 60, how liver function tests should be interpreted in an older adult context, and which lifestyle strategies have the strongest evidence for protecting liver health in later life. For related reading on the broader digestive system, see our guide to digestive health after age 60.

How the Liver Changes Structurally With Age

The liver undergoes several measurable age-related changes independent of disease:

Reduced liver volume: Liver mass decreases by approximately 20–40% between ages 30 and 80 in most studies. This reduction in hepatocyte (liver cell) mass directly reduces the organ’s total processing capacity — both for metabolising drugs and for producing proteins, clotting factors, and bile acids. The reduction is gradual and rarely clinically significant in isolation, but it becomes relevant when the liver is under additional stress from disease, medications, or toxic exposures.

Reduced hepatic blood flow: Blood flow through the liver declines by approximately 25–40% between young adulthood and age 75. This reduced perfusion directly slows the rate at which substances are delivered to hepatocytes for processing — this is particularly relevant for drugs that undergo high first-pass hepatic extraction, where reduced blood flow slows clearance regardless of the enzymatic capacity of the liver cells themselves.

Changes in sinusoidal structure: The liver sinusoids — specialised blood vessels through which blood flows in close contact with hepatocytes — undergo age-related changes including pseudocapillarisation (thickening of the sinusoidal endothelium and loss of the fenestrations that allow efficient exchange of substances between blood and liver cells). These changes reduce the efficiency of lipid metabolism and lipoprotein processing, contributing to age-associated rises in LDL cholesterol and triglycerides.

Mitochondrial dysfunction: Hepatocyte mitochondria — the energy-producing organelles within liver cells — accumulate oxidative damage with age, reducing their efficiency. This contributes to impaired fatty acid oxidation (one reason older livers are more prone to fat accumulation), reduced capacity for energy-intensive hepatic processes, and increased vulnerability to drug-induced liver injury.

Reduced regenerative capacity: The liver retains remarkable regenerative capacity throughout life, but the speed and completeness of regeneration after injury decline with age. This means that recovery from conditions such as acute hepatitis, drug-induced liver injury, or post-surgical liver stress takes longer in older adults.

Age-Related Changes in Drug Metabolism: Why Medication Doses Matter More After 60

One of the most clinically significant consequences of liver aging is altered drug metabolism. The liver is responsible for metabolising most medications through cytochrome P450 (CYP) enzyme systems, and this capacity declines with age through several mechanisms:

Phase I metabolism slowdown: Phase I hepatic metabolism — primarily oxidation, reduction, and hydrolysis reactions carried out by CYP enzymes — decreases with age. CYP3A4, the most abundant CYP enzyme and responsible for metabolising approximately 50% of prescription medications, shows reduced activity with aging. The practical consequence is that drugs primarily cleared by CYP3A4 — including many statins, calcium channel blockers, benzodiazepines, opioids, and some anticoagulants — have longer half-lives in older adults, increasing the risk of accumulation and toxicity at standard adult doses.

Phase II metabolism: Phase II conjugation reactions (glucuronidation, sulfation, acetylation) that prepare metabolites for excretion are generally better preserved with aging than Phase I reactions, though some variability exists.

Drug-drug interaction risk: Polypharmacy — taking multiple medications simultaneously — is more common in older adults and multiplies the complexity of hepatic drug metabolism. Drugs that inhibit or induce CYP enzymes can dramatically alter the effective doses of co-administered medications. Adults over 60 on five or more medications should have their medication list reviewed by a pharmacist for CYP interaction risk at least annually.

Supplement and herbal product interactions: Many commonly used supplements also inhibit CYP enzymes. St. John’s Wort is the most potent CYP3A4 inducer in common supplement use. Grapefruit juice, goldenseal, and high-dose berberine also affect CYP activity meaningfully. Our article on supplements for digestive health covers the evidence and safety profile of common digestive supplements, including liver-specific interactions.

Nonalcoholic Fatty Liver Disease After 60: The Fastest-Growing Liver Concern

Nonalcoholic fatty liver disease (NAFLD) — fat accumulation in the liver in the absence of significant alcohol use — is now the most common liver condition globally and disproportionately affects adults over 60. Its more aggressive form, nonalcoholic steatohepatitis (NASH), involves liver inflammation in addition to fat accumulation and can progress to fibrosis, cirrhosis, and liver cancer.

NAFLD prevalence increases with the components of metabolic syndrome: obesity (particularly central/abdominal adiposity), type 2 diabetes, hypertension, and dyslipidaemia. All of these become more common after 60, driving the elevated NAFLD rates in this age group. Estimates suggest that 30–40% of adults over 60 in Western countries have hepatic steatosis (fat accumulation) detectable on imaging.

Several features of NAFLD are particularly relevant in older adults:

• Silent presentation: Most adults with NAFLD have no symptoms. Fatigue and mild right upper quadrant discomfort are occasionally reported but are non-specific. The condition is most often identified incidentally on abdominal imaging performed for other reasons, or through elevated liver enzymes (ALT, AST) on routine blood tests.
• Fibrosis assessment matters more than steatosis alone: Fat in the liver is common and may not progress. The critical question is whether fibrosis (scarring) is present, since significant fibrosis (stage F3–F4) is what drives the risk of cirrhosis and liver cancer. Non-invasive fibrosis assessment tools — the FIB-4 index (calculated from age, ALT, AST, and platelet count) or elastography (FibroScan) — can identify those at higher risk without liver biopsy.
• NASH-related HCC risk without cirrhosis: Unlike most other liver disease aetiologies, NASH can cause hepatocellular carcinoma even without established cirrhosis, though this is less common. Adults with confirmed NASH should discuss the appropriateness of liver cancer surveillance with their gastroenterologist, as detailed in our guide to liver cancer screening awareness.
• Weight loss is the most effective treatment: A sustained 7–10% reduction in body weight consistently reduces hepatic steatosis, inflammation, and in some studies reverses early fibrosis. For adults over 60, weight loss should be pursued with attention to muscle mass preservation, since sarcopenia (muscle loss) also increases with age and excessively rapid weight loss accelerates it.

Alcohol and the Aging Liver

The aging liver metabolises alcohol less efficiently than the younger liver, primarily because of reduced alcohol dehydrogenase activity and the reduction in hepatic blood flow and hepatocyte mass described earlier. This means the same amount of alcohol produces higher blood alcohol concentrations and greater liver stress in a 65-year-old than the same amount would have produced in the same person at 40.

Current standard guidelines on alcohol consumption — moderate drinking as up to 1 drink per day for women and 2 for men — were derived primarily from studies in middle-aged adults. There is growing expert consensus that these limits are too high for adults over 65, and some major health organisations now recommend lower thresholds or abstinence for older adults, particularly those with any underlying liver condition, taking hepatotoxic medications, or with reduced renal function that affects alcohol clearance. For adults with established liver disease of any cause, alcohol abstinence is the recommendation regardless of age.

Alcohol also interacts with many medications more commonly used by older adults: sedative-hypnotics, antihistamines, opioid pain medications, some diabetes medications, and warfarin all have significant interactions with alcohol that are amplified by the reduced hepatic processing capacity of the aging liver.

Interpreting Liver Function Tests in Adults Over 60

Standard liver function tests — ALT, AST, alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), bilirubin, and albumin — are commonly used but interpreted differently in older adults:

Albumin: Albumin is produced by the liver and its level reflects synthetic function. Albumin levels typically decline slightly with normal aging (partly due to reduced synthesis, partly due to dilution from lower total body water concentration changes). A level that would be considered borderline low in a younger adult may be normal for an older one, but progressive hypoalbuminaemia in an older adult warrants evaluation for malnutrition, chronic illness, or liver disease.

ALP: Alkaline phosphatase rises with normal bone turnover and can be significantly elevated in older adults with bone conditions (osteoporosis, Paget’s disease) or after fractures, independent of liver pathology. An isolated ALP elevation in an older adult should prompt fractionation into liver and bone isoforms before concluding hepatic disease is present.

GGT: GGT is particularly sensitive to alcohol use and to induction by a wide range of medications. In older adults on multiple medications, a mildly elevated GGT may reflect medication-related enzyme induction rather than liver damage — though it warrants attention if trending upward or accompanied by other abnormalities.

ALT and AST in NASH: Many adults with NASH — including those with significant fibrosis — have normal or near-normal ALT levels. Normal ALT does not exclude significant liver disease in older adults with metabolic risk factors. If NAFLD or NASH is suspected, a FIB-4 score provides better fibrosis risk stratification than ALT alone.

Protecting Liver Health After 60: Evidence-Based Strategies

While the liver’s age-related structural changes cannot be reversed, the conditions most likely to accelerate liver damage in older adults — NAFLD, alcohol-related injury, drug-induced liver injury — are significantly modifiable:

Dietary pattern: The Mediterranean diet has the best evidence for liver health among older adults — it reduces hepatic steatosis, lowers liver enzyme levels, and is associated with reduced progression to NASH-related fibrosis in multiple clinical trials. Key components include olive oil as the primary fat source, high vegetable and legume intake, moderate fish consumption, limited red meat, and avoidance of ultra-processed foods and added sugars. Fructose, particularly from sugar-sweetened beverages, is directly lipogenic (fat-producing) in the liver and should be minimised.

Coffee consumption: Caffeinated coffee has the most consistent epidemiological evidence for liver-protective effects of any dietary component, with a dose-dependent inverse relationship with cirrhosis risk and HCC risk across multiple large cohort studies. The mechanism involves caffeine’s inhibition of hepatic fibrogenesis and its antioxidant effects. Two to three cups per day is the quantity most consistently associated with benefit in the literature, though this should be balanced against cardiovascular effects in those with arrhythmia or hypertension.

Physical activity: Regular aerobic exercise reduces hepatic steatosis independently of weight change, through increased hepatic fat oxidation. Both moderate-intensity continuous training (e.g., 150 minutes of brisk walking per week) and resistance training have evidence for liver fat reduction. For older adults, resistance training has the additional benefit of preserving muscle mass, which counteracts the sarcopenia risk associated with dietary calorie restriction for weight loss.

Medication review: Regular review of all medications, supplements, and herbal products for hepatotoxic potential and CYP interaction risk is one of the most impactful and underutilised liver health strategies in older adults. Drug-induced liver injury (DILI) is more common and more severe in older adults. The LiverTox database (NIH) provides detailed hepatotoxicity profiles for thousands of medications and supplements.

Hepatitis B and C status: Adults over 60 who do not know their hepatitis B and C status — particularly those born before 1992 for HBV vaccination availability or between 1945 and 1965 for HCV birth cohort risk — should be tested. Effective treatments exist for both: antiviral therapy for chronic hepatitis B suppresses viral replication and reduces fibrosis progression and HCC risk; direct-acting antivirals (DAAs) for hepatitis C achieve sustained virologic response (cure) in over 95% of treated patients. Testing is inexpensive and a one-time intervention that can prevent significant liver disease. For ongoing liver monitoring recommendations, see our guide on the long-term liver health plan.

Frequently Asked Questions